Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.
Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.
再鼎醫藥股價上漲，公司發佈Q2銷售業績優於預期。此外，公司表示預計具備實質性收入增長和在2025年底之前實現盈利路徑。
Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.
再鼎醫藥股價上漲，公司發佈Q2銷售業績優於預期。此外，公司表示預計具備實質性收入增長和在2025年底之前實現盈利路徑。